Cargando…
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
PURPOSE: To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions...
Autores principales: | Anand, Ernie, Berggren, Lovisa, Deix, Claudia, Tóth, Ágoston, McDonnell, David P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455859/ https://www.ncbi.nlm.nih.gov/pubmed/26064053 http://dx.doi.org/10.2147/NDT.S79347 |
Ejemplares similares
-
Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand, Ernie, et al.
Publicado: (2016) -
Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013) -
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012) -
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014) -
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)